This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, L.-I. Articles by Tien, H.-F. Search for Related Content PubMed PubMed Citation Articles by Lin, L.-I. Articles by Tien, H.-F.

Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells

¹ Graduate Institute of Medical Technology, National Taiwan University and Departments of ² Laboratory Medicine and ³ Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Requests for reprints: Hwei-Fang Tien, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 100. Phone: 886-2-23123456 ext. 3955; Fax: 886-2-23959583; E-mail: hftd{at}ha.mc.ntu.edu.tw.

Purpose: The transcription factor CCAAT/enhancer binding protein , encoded by the CEBPA, is crucial for the differentiation of immature granulocytes. Mutation of the CEBPA may play an important role in leukemogenesis and prognosis. We sought to characterize the CEBPA mutation in acute myeloid leukemia (AML) and to clarify if there is a distinct immunophenotype for leukemic cells with the mutation.

Experiment Design: One hundred and four patients with de novo AML were evaluated for the CEBPA mutation and immunophenotype of the leukemic cells.

Results: Twenty-two distinct mutations were identified in 16 (15%) of 104 AML patients. Fourteen patients had biallelic mutations, mostly involving both the NH₂-terminal TAD1 region and the COOH-terminal basic leucine zipper domain (bZIP). The mutations in the bZIP region were always tandem duplications and were located at hot-spot regions for topoisomerase II sites. Sequential study of the CEBPA mutations showed that the mutations disappeared at complete remission but the same mutations reappeared at relapse. None of the patients developed novel mutations during the follow-up period. Patients with CEBPA mutations had significantly higher incidences of CD7 (73%), CD15 (100%), CD34 (93%), and HLA-DR (93%) expression on the leukemic cells.

Conclusion: These data revealed that most AML with CEBPA mutations were associated with an immunophenotype of HLA-DR⁺CD7⁺CD13⁺CD14^–CD15⁺CD33⁺CD34⁺. The close relationship of CEBPA mutations with the leukemia status of the patients and the concordance of mutation in presenting and relapse samples implicate the CEBPA mutation as a potential marker for monitoring minimal residue disease.

Key Words: CEBPA gene • acute myeloid leukemia • immunophenotyping • minimal residual disease

This article has been cited by other articles:

				M. Raghavan, L.-L. Smith, D. M. Lillington, T. Chaplin, I. Kakkas, G. Molloy, C. Chelala, J.-B. Cazier, J. D. Cavenagh, J. Fitzgibbon, et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia Blood, August 1, 2008; 112(3): 814 - 821. [Abstract] [Full Text] [PDF]

				B. J. Wouters, M. A. Jorda, K. Keeshan, I. Louwers, C. A. J. Erpelinck-Verschueren, D. Tielemans, A. W. Langerak, Y. He, Y. Yashiro-Ohtani, P. Zhang, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1 Blood, November 15, 2007; 110(10): 3706 - 3714. [Abstract] [Full Text] [PDF]

				C. Resende, G. Regalo, C. Duraes, F. Carneiro, and J. C. Machado Genetic Changes of CEBPA in Cancer: Mutations or Polymorphisms? J. Clin. Oncol., June 10, 2007; 25(17): 2493 - 2494. [Full Text] [PDF]

				S. Frohling, A. Corbacioglu, R. F. Schlenk, H. Dohner, and K. Dohner In Reply J. Clin. Oncol., June 10, 2007; 25(17): 2494 - 2495. [Full Text] [PDF]

				B. J. Wouters, I. Louwers, P. J. M. Valk, B. Lowenberg, and R. Delwel A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML Blood, January 1, 2007; 109(1): 389 - 390. [Full Text] [PDF]

				W.-C. Chou, J.-L. Tang, L.-I. Lin, M. Yao, W. Tsay, C.-Y. Chen, S.-J. Wu, C.-F. Huang, R.-J. Chiou, M.-H. Tseng, et al. Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Res., March 15, 2006; 66(6): 3310 - 3316. [Abstract] [Full Text] [PDF]